Published in PLoS Pathog on July 25, 2008
Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies. PLoS Pathog (2012) 1.74
Improved virus neutralization by plant-produced anti-HIV antibodies with a homogeneous beta1,4-galactosylated N-glycan profile. J Biol Chem (2009) 1.49
Tracing HIV-1 transmission: envelope traits of HIV-1 transmitter and recipient pairs. Retrovirology (2016) 1.07
Conformation-dependent recognition of HIV gp120 by designed ankyrin repeat proteins provides access to novel HIV entry inhibitors. J Virol (2013) 0.82
Antiviral activity of recombinant ankyrin targeted to the capsid domain of HIV-1 Gag polyprotein. Retrovirology (2012) 0.82
Toward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challenges. Int J Nanomedicine (2015) 0.82
Crystal structure of an antiviral ankyrin targeting the HIV-1 capsid and molecular modeling of the ankyrin-capsid complex. J Comput Aided Mol Des (2014) 0.79
In vivo binding and retention of CD4-specific DARPin 57.2 in macaques. PLoS One (2010) 0.77
Human immunodeficiency virus type 1 escape from cyclotriazadisulfonamide-induced CD4-targeted entry inhibition is associated with increased neutralizing antibody susceptibility. J Virol (2009) 0.76
Signal peptide-binding drug as a selective inhibitor of co-translational protein translocation. PLoS Biol (2014) 0.76
Delineating CD4 dependency of HIV-1: Adaptation to infect low level CD4 expressing target cells widens cellular tropism but severely impacts on envelope functionality. PLoS Pathog (2017) 0.75
Human Immunodeficiency Virus Immune Cell Receptors, Coreceptors, and Cofactors: Implications for Prevention and Treatment. AIDS Patient Care STDS (2016) 0.75
AnkPlex: algorithmic structure for refinement of near-native ankyrin-protein docking. BMC Bioinformatics (2017) 0.75
Combined Antiviral Therapy Using Designed Molecular Scaffolds Targeting Two Distinct Viral Functions, HIV-1 Genome Integration and Capsid Assembly. Mol Ther Nucleic Acids (2015) 0.75
Discovery and Characterization of a Novel CD4-Binding Adnectin with Potent Anti-HIV Activity. Antimicrob Agents Chemother (2017) 0.75
Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol (2005) 15.61
Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science (1994) 13.54
Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol (1996) 11.91
Determination of lymphocyte division by flow cytometry. J Immunol Methods (1994) 11.48
A method for testing for synergy with any number of agents. J Infect Dis (1978) 9.52
HIV preferentially infects HIV-specific CD4+ T cells. Nature (2002) 9.28
Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med (1998) 8.62
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med (2003) 5.79
Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med (2003) 5.71
A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (2001) 5.38
In vitro selection and evolution of functional proteins by using ribosome display. Proc Natl Acad Sci U S A (1997) 4.71
Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature (2005) 4.71
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med (2003) 4.19
Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science (2004) 3.95
Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med (2007) 3.88
Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol (2005) 3.67
High-affinity binders selected from designed ankyrin repeat protein libraries. Nat Biotechnol (2004) 3.34
Microbicide drug candidates to prevent HIV infection. Lancet (2007) 3.06
Novel anti-CD4 monoclonal antibodies separate human immunodeficiency virus infection and fusion of CD4+ cells from virus binding. J Exp Med (1990) 3.01
Drug export pathway of multidrug exporter AcrB revealed by DARPin inhibitors. PLoS Biol (2007) 2.89
Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. J Mol Biol (2003) 2.81
Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. Annu Rev Med (2008) 2.81
Microbicides: a new approach to preventing HIV and other sexually transmitted infections. Nat Rev Drug Discov (2002) 2.78
Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res Hum Retroviruses (1995) 2.70
Substitution of murine for human CD4 residues identifies amino acids critical for HIV-gp120 binding. Nature (1988) 2.53
Disulfide exchange in domain 2 of CD4 is required for entry of HIV-1. Nat Immunol (2002) 2.28
Antibody and HIV-1 gp120 recognition of CD4 undermines the concept of mimicry between antibodies and receptors. Nature (1992) 2.27
Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5. AIDS (1996) 2.26
Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. J Virol (1999) 2.23
Scientists rethink approach to HIV gels. Nature (2007) 2.14
In vitro and in vivo: the story of nonoxynol 9. J Acquir Immune Defic Syndr (2005) 1.99
Designed to be stable: crystal structure of a consensus ankyrin repeat protein. Proc Natl Acad Sci U S A (2003) 1.98
HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology (2006) 1.97
Inhibition of caspase-2 by a designed ankyrin repeat protein: specificity, structure, and inhibition mechanism. Structure (2007) 1.93
Characterization of recombinant human interleukin-2 with micromethods. J Chromatogr (1985) 1.76
Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus. Clin Diagn Lab Immunol (2001) 1.75
HIV entry inhibitors. Lancet (2007) 1.73
A designed ankyrin repeat protein evolved to picomolar affinity to Her2. J Mol Biol (2007) 1.71
Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors. J Virol (2005) 1.68
Ribosome display: selecting and evolving proteins in vitro that specifically bind to a target. Nat Methods (2007) 1.68
Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion. J Immunol (1992) 1.58
Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J Infect Dis (2004) 1.57
In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10. J Virol (2007) 1.56
The nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells. J Virol (2005) 1.54
Directed in vitro evolution and crystallographic analysis of a peptide-binding single chain antibody fragment (scFv) with low picomolar affinity. J Biol Chem (2004) 1.46
South Africa's experience of the closure of the cellulose sulphate microbicide trial. PLoS Med (2007) 1.40
T Cell Receptor Binding to a pMHCII Ligand Is Kinetically Distinct from and Independent of CD4. J Biol Chem (2000) 1.36
Quantification of infectious HIV-1 plasma viral load using a boosted in vitro infection protocol. Virology (2004) 1.32
Single step protocol to purify recombinant proteins with low endotoxin contents. Protein Expr Purif (2005) 1.32
Dawn of non-nucleoside inhibitor-based anti-HIV microbicides. J Antimicrob Chemother (2006) 1.31
A region in domain 1 of CD4 distinct from the primary gp120 binding site is involved in HIV infection and virus-mediated fusion. J Biol Chem (1991) 1.30
Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines. Immunity (2004) 1.27
The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection. J Infect Dis (2000) 1.26
Intracellular kinase inhibitors selected from combinatorial libraries of designed ankyrin repeat proteins. J Biol Chem (2005) 1.17
Potent T cell activation with dimeric peptide-major histocompatibility complex class II ligand: the role of CD4 coreceptor. J Exp Med (1998) 1.16
Selection and characterization of Her2 binding-designed ankyrin repeat proteins. J Biol Chem (2006) 1.15
Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point. Blood (2004) 1.14
DARPins: a true alternative to antibodies. Curr Opin Drug Discov Devel (2007) 1.13
Development of anti-CD4 MAb hu5A8 for treatment of HIV-1 infection: preclinical assessment in non-human primates. Toxicology (2002) 1.11
A humanized form of a CD4-specific monoclonal antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties. AIDS Res Hum Retroviruses (1997) 1.10
Exploiting common targets in human fertilization and HIV infection: development of novel contraceptive microbicides. Hum Reprod Update (2005) 1.07
Oligomerization of CD4 is required for stable binding to class II major histocompatibility complex proteins but not for interaction with human immunodeficiency virus gp120. Proc Natl Acad Sci U S A (1995) 1.05
In vitro selection and characterization of DARPins and Fab fragments for the co-crystallization of membrane proteins: The Na(+)-citrate symporter CitS as an example. J Struct Biol (2007) 1.03
Carraguard Vaginal Gel Safety in HIV-Positive Women and Men in South Africa. J Acquir Immune Defic Syndr (2007) 1.02
Isolation of intracellular proteinase inhibitors derived from designed ankyrin repeat proteins by genetic screening. J Biol Chem (2006) 0.95
Scientific and policy challenges to development of an AIDS vaccine. Lancet (2007) 0.94
A fusion inhibitor prevents spread of immunodeficiency viruses, but not activation of virus-specific T cells, by dendritic cells. J Virol (2008) 0.93
A highly selected panel of anti-CD4 antibodies fails to induce anti-idiotypic antisera mediating human immunodeficiency virus neutralization. Eur J Immunol (1991) 0.91
Rapid selection of specific MAP kinase-binders from designed ankyrin repeat protein libraries. Protein Eng Des Sel (2006) 0.89
Real-time analysis of human immunodeficiency virus type 1 Env-mediated membrane fusion by fluorescence resonance energy transfer. Microbes Infect (2005) 0.85
The search for a topical dual action spermicide/microbicide. Curr Med Chem (2007) 0.81
Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med (2005) 5.68
Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol (2005) 3.67
HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci U S A (2008) 3.40
High-affinity binders selected from designed ankyrin repeat protein libraries. Nat Biotechnol (2004) 3.34
Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect Dis (2010) 2.98
Drug export pathway of multidrug exporter AcrB revealed by DARPin inhibitors. PLoS Biol (2007) 2.89
Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. J Mol Biol (2003) 2.81
Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc Natl Acad Sci U S A (2002) 2.32
Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. J Infect Dis (2003) 2.17
Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J Virol (2003) 1.97
Inhibition of caspase-2 by a designed ankyrin repeat protein: specificity, structure, and inhibition mechanism. Structure (2007) 1.93
The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. J Virol (2003) 1.86
Allosteric inhibition of aminoglycoside phosphotransferase by a designed ankyrin repeat protein. Structure (2005) 1.75
Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies. PLoS Pathog (2012) 1.74
Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors. J Virol (2005) 1.68
Ribosome display: selecting and evolving proteins in vitro that specifically bind to a target. Nat Methods (2007) 1.68
Entry and transcription as key determinants of differences in CD4 T-cell permissiveness to human immunodeficiency virus type 1 infection. J Virol (2004) 1.68
MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1. J Exp Med (2011) 1.67
Loss of viral control in early HIV-1 infection is temporally associated with sequential escape from CD8+ T cell responses and decrease in HIV-1-specific CD4+ and CD8+ T cell frequencies. J Infect Dis (2004) 1.64
Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection. PLoS Med (2006) 1.61
Efficacy of Carraguard-based microbicides in vivo despite variable in vitro activity. PLoS One (2008) 1.57
In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10. J Virol (2007) 1.56
Profound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infection. PLoS One (2010) 1.50
Directed in vitro evolution and crystallographic analysis of a peptide-binding single chain antibody fragment (scFv) with low picomolar affinity. J Biol Chem (2004) 1.46
Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies. J Exp Med (2011) 1.46
Understanding and making use of human memory B cells. Immunol Rev (2006) 1.46
Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA. Antivir Ther (2011) 1.44
Carrageenan/MIV-150 (PC-815), a combination microbicide. Sex Transm Dis (2007) 1.40
Glancing behind virus load variation in HIV-1 infection. Trends Microbiol (2003) 1.38
HIV-1 transmission after cessation of early antiretroviral therapy among men having sex with men. AIDS (2010) 1.38
Productive human immunodeficiency virus type 1 infection in peripheral blood predominantly takes place in CD4/CD8 double-negative T lymphocytes. J Virol (2007) 1.36
Estimating the stoichiometry of human immunodeficiency virus entry. J Virol (2008) 1.36
A macaque model to study vaginal HSV-2/immunodeficiency virus co-infection and the impact of HSV-2 on microbicide efficacy. PLoS One (2009) 1.35
An antiretroviral/zinc combination gel provides 24 hours of complete protection against vaginal SHIV infection in macaques. PLoS One (2011) 1.35
Quantification of infectious HIV-1 plasma viral load using a boosted in vitro infection protocol. Virology (2004) 1.32
Manipulation of dendritic cell function by viruses. Curr Opin Microbiol (2010) 1.29
Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5). Antimicrob Agents Chemother (2006) 1.27
Astrovirus infection in hospitalized infants with severe combined immunodeficiency after allogeneic hematopoietic stem cell transplantation. PLoS One (2011) 1.27
Rational design of HIV-1 fluorescent hydrolysis probes considering phylogenetic variation and probe performance. J Virol Methods (2010) 1.26
HIV RNA in plasma rebounds within days during structured treatment interruptions. AIDS (2003) 1.25
Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption. PLoS One (2011) 1.24
HIV-1 p24 antigen is a significant inverse correlate of CD4 T-cell change in patients with suppressed viremia under long-term antiretroviral therapy. J Acquir Immune Defic Syndr (2003) 1.24
Zinc acetate/carrageenan gels exhibit potent activity in vivo against high-dose herpes simplex virus 2 vaginal and rectal challenge. Antimicrob Agents Chemother (2011) 1.23
HIV-1 infection of human macrophages directly induces viperin which inhibits viral production. Blood (2012) 1.21
Double-stranded RNA analog poly(I:C) inhibits human immunodeficiency virus amplification in dendritic cells via type I interferon-mediated activation of APOBEC3G. J Virol (2008) 1.21
HIV sensitivity to neutralization is determined by target and virus producer cell properties. AIDS (2009) 1.21
Resolution of de novo HIV production and trafficking in immature dendritic cells. Nat Methods (2007) 1.21
Human immunodeficiency virus-specific CD8(+) T-cell responses do not predict viral growth and clearance rates during structured intermittent antiretroviral therapy. J Virol (2002) 1.20
In vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers. J Virol (2007) 1.20
HIV-1 superinfection in an HIV-2-infected woman with subsequent control of HIV-1 plasma viremia. Clin Infect Dis (2009) 1.18
RANTES (CCL5) uses the proteoglycan CD44 as an auxiliary receptor to mediate cellular activation signals and HIV-1 enhancement. Blood (2003) 1.18
Systemic antibody responses to gut commensal bacteria during chronic HIV-1 infection. Gut (2011) 1.18
DARPins: a new generation of protein therapeutics. Drug Discov Today (2008) 1.17
A single dose of a MIV-150/Zinc acetate gel provides 24 h of protection against vaginal simian human immunodeficiency virus reverse transcriptase infection, with more limited protection rectally 8-24 h after gel use. AIDS Res Hum Retroviruses (2012) 1.16
Identification of personal lubricants that can cause rectal epithelial cell damage and enhance HIV type 1 replication in vitro. AIDS Res Hum Retroviruses (2011) 1.14
The frequency of α₄β₇(high) memory CD4⁺ T cells correlates with susceptibility to rectal simian immunodeficiency virus infection. J Acquir Immune Defic Syndr (2013) 1.14
Immune senescence: relative contributions of age and cytomegalovirus infection. PLoS Pathog (2012) 1.13
DARPins: a true alternative to antibodies. Curr Opin Drug Discov Devel (2007) 1.13
HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss. J Acquir Immune Defic Syndr (2005) 1.07
TNF-alpha induces macroautophagy and regulates MHC class II expression in human skeletal muscle cells. J Biol Chem (2010) 1.05
Residual cell-associated unspliced HIV-1 RNA in peripheral blood of patients on potent antiretroviral therapy represents intracellular transcripts. Antivir Ther (2002) 1.05
The nonnucleoside reverse transcription inhibitor MIV-160 delivered from an intravaginal ring, but not from a carrageenan gel, protects against simian/human immunodeficiency virus-RT Infection. AIDS Res Hum Retroviruses (2012) 1.04
N-linked glycosylation facilitates sialic acid-independent attachment and entry of influenza A viruses into cells expressing DC-SIGN or L-SIGN. J Virol (2010) 1.03
Mobilization of HIV spread by diaphanous 2 dependent filopodia in infected dendritic cells. PLoS Pathog (2012) 1.01
Tailored enrichment strategy detects low abundant small noncoding RNAs in HIV-1 infected cells. Retrovirology (2012) 1.01
Functional discrepancies in HIV-specific CD8+ T-lymphocyte populations are related to plasma virus load. J Clin Immunol (2002) 0.99
HSV-2 infection of dendritic cells amplifies a highly susceptible HIV-1 cell target. PLoS Pathog (2011) 0.99
A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J Infect Dis (2002) 0.99
Structure of wild-type Plk-1 kinase domain in complex with a selective DARPin. Acta Crystallogr D Biol Crystallogr (2008) 0.97
Shifts in cell-associated HIV-1 RNA but not in episomal HIV-1 DNA correlate with new cycles of HIV-1 infection in vivo. Antivir Ther (2003) 0.97